VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) and Kyntra Bio (NASDAQ:KYNB – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.
Institutional and Insider Ownership
78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares VistaGen Therapeutics and Kyntra Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VistaGen Therapeutics | $1.27 million | 8.50 | -$69.68 million | ($1.66) | -0.15 |
| Kyntra Bio | $4.62 million | 7.04 | $183.45 million | $45.30 | 0.18 |
Kyntra Bio has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for VistaGen Therapeutics and Kyntra Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
| Kyntra Bio | 1 | 1 | 3 | 0 | 2.40 |
VistaGen Therapeutics currently has a consensus target price of $0.95, indicating a potential upside of 290.62%. Kyntra Bio has a consensus target price of $36.00, indicating a potential upside of 348.32%. Given Kyntra Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio is more favorable than VistaGen Therapeutics.
Profitability
This table compares VistaGen Therapeutics and Kyntra Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
Risk & Volatility
VistaGen Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Summary
Kyntra Bio beats VistaGen Therapeutics on 12 of the 14 factors compared between the two stocks.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
